The Oncologic Drugs Advisory Committee held its first session since President Trump’s inauguration, with a two-day, back-to-back marathon meeting, signaling a return to business at FDA after significant upheaval at the agency.
Wafik El-Deiry, director of the Legorreta Cancer Center at Brown University, joined The Cancer Letter’s weekly podcast to discuss his recent guest editorial—and confirmed his candidacy for director of the National Cancer Institute.
Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
Peer review, registries, and evidence-based patient information have taken a hit in Trump’s first 100 days in office.
The Cancer Letter has covered—and will continue to cover—all the ways in which the current administration is fundamentally reshaping cancer research in the U.S. But this week, The Cancer Letter and the podcast focused on a patient story.
The National Cancer Registries Program, or NPCR, is a relatively small but highly impactful 33-year-old CDC program that gauges disparities in cancer and tracks progress against the disease. So, why was it left out of the Trump administration’s preliminary budget?
A confidential Trump administration budget document obtained by The Cancer Letter called for a 40% budget cut to NIH and a restructuring of the 27 existing NIH institutes and centers down to just eight. But what else is in it?
Speaking on The Cancer Letter Podcast, Taofeek Kunle Owonikoko recalled recent conversations with two junior faculty members at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
